|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...5960616263646566676869...156157» |
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed: Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=400, Active, not recruiting, Sponsor: Biogen
Enrolling by invitation --> Active, not recruiting
- Trial completion: ANSG: Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS (clinicaltrials.gov) - Aug 11, 2015
P4, N=30, Completed, Sponsor: Jochen Vehoff
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate (clinicaltrials.gov) - Aug 11, 2015
P2, N=112, Completed, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Completed | N=140 --> 112
- ||| dimethyl fumarate / Generic mfg.
New trial, Review: REALIZE: Tecfidera Lymphocyte Chart Review (clinicaltrials.gov) - Aug 10, 2015
P=N/A, N=1500, Recruiting, Sponsor: Biogen
- | buprenorphine transdermal / Generic mfg.
New P4 trial: Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity (clinicaltrials.gov) - Aug 10, 2015
P4, N=78, Completed, Sponsor: Mundipharma Pharmaceuticals Sdn. Bhd.
- |||| vobarilizumab (ALX-0061) / Sanofi
Enrollment open: A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Aug 7, 2015
P2, N=300, Recruiting, Sponsor: Ablynx
Recruiting --> Completed | N=140 --> 112 Not yet recruiting --> Recruiting
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
New trial: BEER: How to be Safe With Alcoholic Drinks in Diabetes (clinicaltrials.gov) - Aug 7, 2015
P=N/A, N=24, Not yet recruiting, Sponsor: Kinderkrankenhaus auf der Bult
- | Bioferon (interferon alpha 2b) / Biosidus, Rebif (human IFN-?-1a) / EMD Serono
New P1 trial: Phase I BP Interferon (IFN) Beta-004 (clinicaltrials.gov) - Aug 7, 2015
P1, N=24, Completed, Sponsor: Centre Hospitalier Universitaire Vaudois
- |||| Xarelto (rivaroxaban) / J&J
Enrollment open, Trial initiation date: RAPS: Rivaroxaban for Antiphospholipid Antibody Syndrome (clinicaltrials.gov) - Aug 6, 2015
P4, N=150, Recruiting, Sponsor: St. Joseph's Healthcare Hamilton
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Sep 2014
- | bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Enrollment open: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Aug 5, 2015
P2, N=15, Recruiting, Sponsor: Immune Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- New trial: NISSC: EBMT ADWP Prospective Non Interventional Study : AutoHSCT in SSc Patients (clinicaltrials.gov) - Aug 5, 2015
P=N/A, N=50, Recruiting, Sponsor: European Group for Blood and Marrow Transplantation
- New P2 trial: Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon (clinicaltrials.gov) - Aug 5, 2015
P2, N=35, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | Bioferon (interferon alpha 2b) / Biosidus
New P1 trial: Phase I BP Interferon (IFN) Beta-001 (clinicaltrials.gov) - Aug 5, 2015
P1, N=12, Completed, Sponsor: Centre Hospitalier Universitaire Vaudois
- |||||||||| Rixathon (rituximab biosimilar) / Kyowa Kirin, Sandoz
New P3 trial: ASSIST-RT: GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan (clinicaltrials.gov) - Aug 4, 2015
P3, N=100, Recruiting, Sponsor: Sandoz
- |||||||||| blisibimod (A-623) / Anthera Pharma
New P3 trial: CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis (clinicaltrials.gov) - Aug 4, 2015
P3, N=350, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
- | BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia
New P1 trial: Postprandial Blood Glucose Control With BioChaperone (clinicaltrials.gov) - Aug 4, 2015
P1, N=28, Recruiting, Sponsor: Adocia
- | prezalumab (AMG 557) / Amgen, AstraZeneca
Enrollment open: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Aug 3, 2015
P2, N=42, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Enrollment open: Sudoscan in Patients With Autoimmune Disorders (clinicaltrials.gov) - Aug 1, 2015
P=N/A, N=100, Recruiting, Sponsor: The Catholic University of Korea
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| AZD9567 / AstraZeneca
New P1 trial: A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567. (clinicaltrials.gov) - Jul 31, 2015
P1, N=72, Not yet recruiting, Sponsor: AstraZeneca
- Enrollment open: ENHANCE: MS Symptom Management Study (clinicaltrials.gov) - Jul 31, 2015
P=N/A, N=30, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| CHS-0214 (etanercept biosimilar) / Coherus Biosci
Enrollment open: A Long Term Safety Extension Study (CHS-0214-05) (clinicaltrials.gov) - Jul 31, 2015
P3, N=400, Recruiting, Sponsor: Coherus Biosciences, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment open: PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) (clinicaltrials.gov) - Jul 29, 2015
P1, N=22, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Clinical: A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jul 29, 2015
P2, N=62, Recruiting, Sponsor: Grifols Therapeutics Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Apidra (insulin glulisine) / Sanofi
New P2 trial: SHAN: Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children (clinicaltrials.gov) - Jul 28, 2015
P2, N=24, Recruiting, Sponsor: University Hospital, Montpellier
- ||| New trial: WEB-PaMS: WEB-Based Physiotherapy for People With Multiple Sclerosis (clinicaltrials.gov) - Jul 27, 2015
P=N/A, N=90, Recruiting, Sponsor: University of Glasgow
- ||| New trial: Bump2Be: BGAT (Blood Glucose Awareness Training) for Users Who Might Become Pregnant (clinicaltrials.gov) - Jul 27, 2015
P=N/A, N=58, Not yet recruiting, Sponsor: University of Virginia
- Enrollment closed: IMMUNOSEP: Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 26, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification: REACH RA: Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice (clinicaltrials.gov) - Jul 26, 2015
P=N/A, N=140, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Phase classification: P4 --> P=N/A
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New trial, HEOR: An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab (clinicaltrials.gov) - Jul 25, 2015
P=N/A, N=94, Completed, Sponsor: Hoffmann-La Roche
- | New P1 trial: Open-label Study of Liothyronine in MS (clinicaltrials.gov) - Jul 23, 2015
P1, N=20, Recruiting, Sponsor: Johns Hopkins University
- |||||| Abrilada (adalimumab-afzb) / Pfizer
Enrollment open, Combination therapy: A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02). (clinicaltrials.gov) - Jul 23, 2015
P3, N=560, Recruiting, Sponsor: Pfizer
Phase classification: P4 --> P=N/A Not yet recruiting --> Recruiting
- ||| New trial: The ANCA Vasculitis Questionnaire (AAV-PRO (clinicaltrials.gov) - Jul 23, 2015
P=N/A, N=500, Recruiting, Sponsor: University of Pennsylvania
- Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
New P1 trial: PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes (clinicaltrials.gov) - Jul 23, 2015
P1, N=40, Not yet recruiting, Sponsor: Gan and Lee Pharmaceuticals
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 22, 2015
P3, N=60, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change, Trial termination: BiobankII: Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jul 22, 2015
P4, N=8, Terminated, Sponsor: Heinrich-Heine University, Duesseldorf
Recruiting --> Completed N=250 --> 8 | Recruiting --> Terminated; lack of recruitment
- Campath (alemtuzumab) / Sanofi
Enrollment change, Trial termination, Trial primary completion date: Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases (clinicaltrials.gov) - Jul 22, 2015
P1, N=4, Terminated, Sponsor: Duke University
N=250 --> 8 | Recruiting --> Terminated; lack of recruitment N=20 --> 4 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Jul 2015; low accrual
- || Lupuzor (rigerimod) / ImmuPharma, Alora Pharma
New P3 trial: A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 22, 2015
P3, N=200, Not yet recruiting, Sponsor: ImmuPharma
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, Trial completion: Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis (clinicaltrials.gov) - Jul 22, 2015
P3, N=316, Completed, Sponsor: Astellas Pharma Inc
N=20 --> 4 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Jul 2015; low accrual Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: ORIENT: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Initiation date: Jun 2015 --> Oct 2015
- Biomarker, Enrollment change, Trial termination, Trial primary completion date: CYTOSEP: Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=101, Terminated, Sponsor: University Hospital, Montpellier
Initiation date: Jun 2015 --> Oct 2015 N=200 --> 101 | Recruiting --> Terminated | Trial primary completion date: Jun 2012 --> Jun 2011; Results obtained are sufficient for a publication.
- | tabalumab (LY2127399) / Eli Lilly
Trial completion: A Study of LY2127399 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 21, 2015
P3, N=1124, Completed, Sponsor: Eli Lilly and Company
N=200 --> 101 | Recruiting --> Terminated | Trial primary completion date: Jun 2012 --> Jun 2011; Results obtained are sufficient for a publication. Active, not recruiting --> Completed
- | tabalumab (LY2127399) / Eli Lilly
Trial completion: A Study of LY2127399 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 21, 2015
P3, N=1164, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Carbohydrate Counting in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=87, Recruiting, Sponsor: Fondation Lenval
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Sep 2016
- Trial primary completion date: Is a Diet Necessary When Corticosteroid Treatment is Prescribed? (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=170, Active, not recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Apr 2015 --> Sep 2016 Trial primary completion date: May 2015 --> Sep 2015
- prezalumab (AMG 557) / Amgen, AstraZeneca
Enrollment closed, Enrollment change: Safety Study of AMG 557 in Subjects With Lupus Arthritis (clinicaltrials.gov) - Jul 21, 2015
P1, N=20, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: May 2015 --> Sep 2015 Recruiting --> Active, not recruiting | N=40 --> 20
- New trial: EP3PGKG: Estimation of Pentraxin3 and PGingivalis Levels in Patients With Knee Joint and Gum Diseases (clinicaltrials.gov) - Jul 20, 2015
P=N/A, N=90, Recruiting, Sponsor: Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
- | ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
New P3 trial: A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (clinicaltrials.gov) - Jul 20, 2015
P3, N=0, Recruiting, Sponsor: Kissei Pharmaceutical Co., Ltd.
- | ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
New P3 trial: An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (clinicaltrials.gov) - Jul 20, 2015
P3, N=0, Recruiting, Sponsor: Kissei Pharmaceutical Co., Ltd.
- | ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
New P3 trial: A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (clinicaltrials.gov) - Jul 20, 2015
P3, N=0, Recruiting, Sponsor: Kissei Pharmaceutical Co., Ltd.
- ||| remtolumab (ABT-122) / AbbVie
Enrollment closed, P2 data, Trial primary completion date: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jul 20, 2015
P2, N=160, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting | N=40 --> 20 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Oct 2015